Overview

A Phase I Study of LuoXin Innovate (LXI-15028) in Healthy Chinese Subjects to Evaluate the Pharmacokinetics, Safety and Tolerability.

Status:
Completed
Trial end date:
2018-05-08
Target enrollment:
Participant gender:
Summary
"This study is a single-center, randomized, double-blinded and placebo-controlled trial designed not only to assess pharmacokinetics, safety and tolerability of LXI-15028 but also to evaluate the pharmacokinetic characteristics of main metabolite M1 in vivo in 38 healthy adult Chinese subjects after receiving escalating single oral doses of 50 mg, 100 mg and 200 mg and multiple oral doses of 100 mg of LXI-15028.
Phase:
Phase 1
Details
Lead Sponsor:
Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.